Stephen K. Tyring

25.4k total citations · 7 hit papers
407 papers, 16.8k citations indexed

About

Stephen K. Tyring is a scholar working on Epidemiology, Dermatology and Immunology. According to data from OpenAlex, Stephen K. Tyring has authored 407 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Epidemiology, 112 papers in Dermatology and 92 papers in Immunology. Recurrent topics in Stephen K. Tyring's work include Herpesvirus Infections and Treatments (79 papers), Dermatology and Skin Diseases (63 papers) and Psoriasis: Treatment and Pathogenesis (56 papers). Stephen K. Tyring is often cited by papers focused on Herpesvirus Infections and Treatments (79 papers), Dermatology and Skin Diseases (63 papers) and Psoriasis: Treatment and Pathogenesis (56 papers). Stephen K. Tyring collaborates with scholars based in United States, Canada and Germany. Stephen K. Tyring's co-authors include Kim Papp, Peter L. Rady, István Arany, Richard G. Langley, Craig L. Leonardi, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Ralph Zitnik and Reuben Matalon and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Stephen K. Tyring

391 papers receiving 16.2k citations

Hit Papers

Secukinumab in Plaque Pso... 2002 2026 2010 2018 2014 2005 2007 2002 2005 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
    2014 1.5k citations Richard G. Langley, Mark Lebwohl et al. profile →
  2. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
    2005 852 citations Stephen K. Tyring, Kim Papp et al. profile →
  3. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    2007 695 citations Stephen K. Tyring, Alexa B. Kimball et al. Journal of the American Academy of Dermatology profile →
  4. Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
    2002 583 citations Stephen K. Tyring et al. profile →
  5. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
    2005 557 citations Kim Papp, Stephen K. Tyring et al. British Journal of Dermatology profile →
  6. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    2017 413 citations Kristian Reich, Kim Papp et al. profile →
  7. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    2017 392 citations Kim Papp, Andrew Blauvelt et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stephen K. Tyring 6.8k 5.7k 4.8k 2.4k 2.0k 407 16.8k
Lars E. French 7.3k 1.1× 3.8k 0.7× 5.2k 1.1× 4.4k 1.8× 6.7k 3.3× 482 21.2k
Sarah L. Gaffen 10.9k 1.6× 3.5k 0.6× 1.7k 0.3× 2.5k 1.0× 3.3k 1.6× 150 18.4k
Thomas Ruzicka 6.2k 0.9× 3.8k 0.7× 11.9k 2.5× 3.3k 1.4× 5.7k 2.8× 672 26.2k
Enrico Maggi 15.6k 2.3× 2.6k 0.5× 2.6k 0.6× 3.9k 1.6× 3.6k 1.8× 367 27.2k
Francesco Annunziato 10.8k 1.6× 1.8k 0.3× 1.2k 0.2× 3.4k 1.4× 3.3k 1.6× 209 18.9k
Jean‐Christophe Renauld 13.8k 2.0× 1.9k 0.3× 1.5k 0.3× 4.6k 1.9× 3.7k 1.8× 243 20.5k
Raif S. Geha 19.4k 2.9× 2.4k 0.4× 4.3k 0.9× 2.7k 1.1× 5.3k 2.6× 501 31.8k
Sergio Romagnani 20.6k 3.0× 3.7k 0.6× 3.3k 0.7× 4.9k 2.0× 4.7k 2.3× 350 36.0k
Wenjun Ouyang 14.2k 2.1× 1.9k 0.3× 1.8k 0.4× 4.6k 1.9× 5.6k 2.7× 123 22.8k
Padraic G. Fallon 11.5k 1.7× 1.4k 0.2× 2.2k 0.5× 1.2k 0.5× 2.9k 1.4× 219 20.2k

Countries citing papers authored by Stephen K. Tyring

Since Specialization
Citations

This map shows the geographic impact of Stephen K. Tyring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen K. Tyring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen K. Tyring more than expected).

Fields of papers citing papers by Stephen K. Tyring

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen K. Tyring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen K. Tyring. The network helps show where Stephen K. Tyring may publish in the future.

Co-authorship network of co-authors of Stephen K. Tyring

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen K. Tyring. A scholar is included among the top collaborators of Stephen K. Tyring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen K. Tyring. Stephen K. Tyring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patel, Anisha B., et al.. (2024). Resolution of metastatic cutaneous Crohn's disease with upadacitinib monotherapy. JAAD Case Reports. 46. 81–84.
2.
Gold, Linda Stein, Stephen K. Tyring, Hwanhee Hong, et al.. (2024). 50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study. Journal of the American Academy of Dermatology. 91(3). AB38–AB38.
3.
Feldman, Steven R., George Han, Valerie Callender, et al.. (2024). Benefit of Topical Combination Therapy for Acne: Analyzing Effect Size Using Number Needed to Treat. Journal of Drugs in Dermatology. 23(2). 42–49. 1 indexed citations
4.
Blauvelt, Andrew, David M. Pariser, Stephen K. Tyring, et al.. (2023). Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. Journal of Dermatological Science. 109(1). 12–21. 11 indexed citations
5.
Tyring, Stephen K., et al.. (2023). Buffalopox: An emerging cutaneous disease in humans. Journal of the European Academy of Dermatology and Venereology. 39(2). 404–406. 1 indexed citations
6.
Bubak, Andrew N., Cheryl L. Beseler, Christina N. Como, et al.. (2020). Acute zoster plasma contains elevated amyloid, correlating with Aβ42 and amylin levels, and is amyloidogenic. Journal of NeuroVirology. 26(3). 422–428. 11 indexed citations
7.
Lewis, Daniel J., Ramya Vangipuram, Uyen Ngoc Mui, et al.. (2019). The efficacy of omalizumab in Cutaneous Mastocytosis: A case series. Dermatologic Therapy. 32(3). e12848–e12848. 8 indexed citations
8.
9.
Huang, Simo, Julie H. Wu, Daniel J. Lewis, Peter L. Rady, & Stephen K. Tyring. (2018). A novel approach to the classification of epidermodysplasia verruciformis. International Journal of Dermatology. 57(11). 1344–1350. 29 indexed citations
10.
Blauvelt, Andrew, Kristian Reich, Kim Papp, et al.. (2018). Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. British Journal of Dermatology. 179(3). 615–622. 60 indexed citations
11.
Langley, Richard G., April W. Armstrong, Mark Lebwohl, et al.. (2018). Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. British Journal of Dermatology. 180(2). 306–314. 23 indexed citations
12.
Papp, Kim, Alexa B. Kimball, Andrew Blauvelt, et al.. (2018). EFFECT OF TILDRAKIZUMAB ON PERSONAL RELATIONSHIPS IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS. 98. 1 indexed citations
13.
14.
Wald, Anna, Amalia Magaret, Terri Warren, et al.. (2016). Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences A Randomized Clinical Trial. Publisher. 4 indexed citations
15.
Cohen, Daniel N., Aaron C. Shaver, Liping Du, et al.. (2015). Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clinical Cancer Research. 21(11). 2624–2634. 23 indexed citations
16.
Gordon, Rachel, et al.. (2012). Biologic therapy and risk of infection.. PubMed. 17(4). 1–4. 4 indexed citations
17.
Wang, Lin, Sankar Surendran, Kimberlee Michals‐Matalon, et al.. (2007). Mutations in the Regulatory Domain of Phenylalanine Hydroxylase and Response to Tetrahydrobiopterin. Genetic Testing. 11(2). 174–178. 8 indexed citations
18.
Tyring, Stephen K., et al.. (2002). The management of herpes simplex virus infections. Current Opinion in Infectious Diseases. 15(2). 115–122. 14 indexed citations
19.
Arany, István, Peter L. Rady, & Stephen K. Tyring. (1993). Alterations in Cytokine/Antioncogene Expression in Skin Lesions Caused by "Low-Risk" Types of Human Papillomaviruses. Viral Immunology. 6(4). 255–265. 19 indexed citations
20.
Rady, Peter L., Franco Scinicariello, Richard F. Wagner, & Stephen K. Tyring. (1992). p53 mutations in basal cell carcinomas.. PubMed. 52(13). 3804–6. 178 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lars E. French Breakdown of academic impact, for papers by Sarah L. Gaffen Breakdown of academic impact, for papers by Thomas Ruzicka Breakdown of academic impact, for papers by Enrico Maggi Breakdown of academic impact, for papers by Francesco Annunziato Breakdown of academic impact, for papers by Jean‐Christophe Renauld Breakdown of academic impact, for papers by Raif S. Geha Breakdown of academic impact, for papers by Sergio Romagnani Breakdown of academic impact, for papers by Wenjun Ouyang Breakdown of academic impact, for papers by Padraic G. Fallon
Rankless by CCL
2026